An anti-IgE monoclonal antibody that binds to IgE on CD23 but not on high-affinity IgE.Fc receptors

Immunobiology

Volumn 217, Issue 7, 2012, Pages 676-683

  Shiung, Yu Yu ^a,b   Chiang, Chen Yi ^b   Chen, Jiun Bo ^b   Wu, Pheidias C ^a,b   Hung, Alfur Fu Hsin ^a,b   Lu, Donic Chien Sheng ^b   Pan, Rong Long ^a   Chang, Tse Wen ^b  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Allergy; Anti IgE; Basophils; CD23; Fce open RI; IgE; Omalizumab

Indexed keywords

CD23 ANTIGEN; EPITOPE; FC EPSILON RI RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 8D6; OMALIZUMAB; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ALPHA CHAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BASOPHIL; BINDING AFFINITY; BINDING COMPETITION; CELL ACTIVATION; CONTROLLED STUDY; DEGRANULATION; DOWN REGULATION; DRUG COMPETITION; DRUG MECHANISM; DRUG PROTEIN BINDING; EMBRYO; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; RAT;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY SPECIFICITY; B-LYMPHOCYTES; BASOPHILS; BINDING, COMPETITIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; MAST CELLS; MICE; MICE, INBRED BALB C; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTORS, IGE;

EID: 84861195053     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.11.006     Document Type: Article

References (35)

1. Beavil A.J., Edmeades R.L., Gould H.J., Sutton B.J. Alpha-helical coiled-coil stalks in the low-affinity receptor for IgE (Fc epsilon RII/CD23) and related C-type lectins. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:753-757.
2. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., Saini S. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J. Allergy Clin. Immunol. 2004, 114:527-530.
3. Bonnefoy J.Y., Shields J., Mermod J.J. Inhibition of human interleukin 4-induced IgE synthesis by a subset of anti-CD23/Fc epsilon RII monoclonal antibodies. Eur. J. Immunol. 1990, 20:139-144.
4. Byrd J.C., O'Brien S., Flinn I.W., Kipps T.J., Weiss M., Rai K., Lin T.S., Woodworth J., Wynne D., Reid J., Molina A., Leigh B., Harris S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res. 2007, 13:4448-4455.
5. Chang T.W. The pharmacological basis of anti-IgE therapy. Nat. Biotechnol. 2000, 18:157-162.
6. Chang T.W., Shiung Y.Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. J. Allergy Clin. Immunol. 2006, 117:1203-1212. quiz 1213.
7. Chang T.W., Wu P.C., Hsu C.L., Hung A.F. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv. Immunol. 2007, 93:63-119.
8. Chen J.B., Wu P.C., Hung A.F., Chu C.Y., Tsai T.F., Yu H.M., Chang H.Y., Chang T.W. Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells. J. Immunol. 2010, 184:1748-1756.
9. Conrad D.H. Fc epsilon RII/CD23: the low affinity receptor for IgE. Annu. Rev. Immunol. 1990, 8:623-645.
10. Conrad D.H., Ford J.W., Sturgill J.L., Gibb D.R. CD23: an overlooked regulator of allergic disease. Curr. Allergy Asthma Rep. 2007, 7:331-337.
11. Davis F.M., Gossett L.A., Pinkston K.L., Liou R.S., Sun L.K., Kim Y.W., Chang N.T., Chang T.W., Wagner K., Bews J., et al. Can anti-IgE be used to treat allergy?. Springer Semin. Immunopathol. 1993, 15:51-73.
12. Ford J.W., Kilmon M.A., Haas K.M., Shelburne A.E., Chan-Li Y., Conrad D.H. In vivo murine CD23 destabilization enhances CD23 shedding and IgE synthesis. Cell. Immunol. 2006, 243:107-117.
13. Gold D.R., Wright R. Population disparities in asthma. Annu. Rev. Public Health 2005, 26:89-113.
14. Gould H.J., Sutton B.J. IgE in allergy and asthma today. Nat. Rev. Immunol. 2008, 8:205-217.
15. Griffith Q.K., Liang Y., Onguru D.O., Mwinzi P.N., Ganley-Leal L.M. CD23-bound IgE augments and dominates recall responses through human naive B cells. J. Immunol. 2011, 186:1060-1067.
16. Hart T.K., Blackburn M.N., Brigham-Burke M., Dede K., Al-Mahdi N., Zia-Amirhosseini P., Cook R.M. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 2002, 130:93-100.
17. Hibbert R.G., Teriete P., Grundy G.J., Beavil R.L., Reljic R., Holers V.M., Hannan J.P., Sutton B.J., Gould H.J., McDonnell J.M. The structure of human CD23 and its interactions with IgE and CD21. J. Exp. Med. 2005, 202:751-760.
18. Holgate S., Buhl R., Bousquet J., Smith N., Panahloo Z., Jimenez P. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir. Med. 2009, 103:1098-1113.
19. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J. Allergy Clin. Immunol. 2005, 115:459-465.
20. Isolauri E., Huurre A., Salminen S., Impivaara O. The allergy epidemic extends beyond the past few decades. Clin. Exp. Allergy 2004, 34:1007-1010.
21. Lanier B. Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Allergy Asthma Proc. 2006, 27:S37-S42.
22. Lanier B.Q., Corren J., Lumry W., Liu J., Fowler-Taylor A., Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann. Allergy. Asthma. Immunol. 2003, 91:154-159.
23. Lemieux G.A., Blumenkron F., Yeung N., Zhou P., Williams J., Grammer A.C., Petrovich R., Lipsky P.E., Moss M.L., Werb Z. The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10. J. Biol. Chem. 2007, 282:14836-14844.
24. Milgrom H., Fick R.B., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., Metzger W.J. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N. Engl. J. Med. 1999, 341:1966-1973.
25. Nakamura T., Kloetzer W.S., Brams P., Hariharan K., Chamat S., Cao X., LaBarre M.J., Chinn P.C., Morena R.A., Shestowsky W.S., Li Y.P., Chen A., Reff M.E. In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain. Int. J. Immunopharmacol. 2000, 22:131-141.
26. Niiro H., Clark E.A. Regulation of B-cell fate by antigen-receptor signals. Nat. Rev. Immunol. 2002, 2:945-956.
27. + lymphoma cell lines. Blood 2008, 111:1594-1602.
28. Poole J.A., Meng J., Reff M., Spellman M.C., Rosenwasser L.J. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J. Allergy Clin. Immunol. 2005, 116:780-788.
29. Rafi A., Do L.T., Katz R., Sheinkopf L.E., Simons C.W., Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc. 2010, 31:76-83.
30. Rosenwasser L.J., Busse W.W., Lizambri R.G., Olejnik T.A., Totoritis M.C. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single-dose, dose-escalating clinical trial. J. Allergy Clin. Immunol. 2003, 112:563-570.
31. Rosenwasser L.J., Meng J. Anti-CD23. Clin. Rev. Allergy Immunol. 2005, 29:61-72.
32. Stokes J., Casale T.B. Rationale for new treatments aimed at IgE immunomodulation. Ann. Allergy. Asthma. Immunol. 2004, 93:212-217. quiz 217-219, 271.
33. Wiegand T.W., Williams P.B., Dreskin S.C., Jouvin M.H., Kinet J.P., Tasset D. High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J. Immunol. 1996, 157:221-230.
34. Wisdom G.B. Methods in Molecular Biology. Conjugation of Antibodies to Horseradish Peroxidase. 2005, vol. 295:127-130. Humana Press.
35. Yabuuchi S., Nakamura T., Kloetzer W.S., Reff M.E. Anti-CD23 monoclonal antibody inhibits germline Cepsilon transcription in B cells. Int. Immunopharmacol. 2002, 2:453-461.